Coupled with mounting evidence regarding the synergy between CD40 agonists and other immunotherapies, these results advocate for further exploration of CD40-based interventions tailored to specific tumor types and unique molecular and immunologic profiles. This evidence concerns the gene CD40 and neoplasm.